Q32 Bio Inc.

Equities

QTTB

US7469641051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
26.22 ^USD	+16.84%		+36.42%	+139.58%

Jul. 09	Q32 Bio Completes Enrollment in Mid-Stage Atopic Dermatitis Trial	MT
Jul. 09	Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis	CI

Homology Medicines, Inc. Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria and Hunter Syndrome (Mps Ii)

January 06, 2021 at 08:00 am EST

Homology Medicines, Inc. announced plans to progress its gene therapy and gene editing platform, and unveiled plans to have three clinical programs and a development candidate in a new therapeutic area during 2021.

Latest news about Q32 Bio Inc.

Q32 Bio Completes Enrollment in Mid-Stage Atopic Dermatitis Trial	Jul. 09	MT
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis	Jul. 09	CI
Q32 Bio Added to Russell 3000 Index	Jul. 01	MT
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Small Cap Completeness Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2000 Value Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000 Value Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2000 Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000E Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2500 Value Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Microcap Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2000 Dynamic Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell Microcap Value Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000E Value Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 2500 Index	Jun. 30	CI
Q32 Bio Inc.(NasdaqGM:QTTB) added to Russell 3000 Index	Jun. 30	CI
Guggenheim Initiates Q32 Bio at Buy With $100 Price Target	Jun. 17	MT
Leerink Partners Starts Q32 Bio With Outperform Rating	May. 21	MT
Q32 Bio Inc. Provides Corporate Update	May. 09	CI
Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	Apr. 11	MT
Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	Apr. 03	CI
Piper Sandler Initiates Q32 Bio With Overweight Rating, $45 Price Target	Apr. 02	MT
Q32 Bio Inc.(NasdaqGM:QTTB) added to NASDAQ Composite Index	Mar. 25	CI
Homology Medicines, Inc.(NasdaqGS:FIXX) dropped from NASDAQ Composite Index	Mar. 24	CI
Q32 Bio Inc. announced that it has received $42 million in funding from a group of investors	Mar. 24	CI

Chart Q32 Bio Inc.

Duration

Period

More charts

Company Profile

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.22 USD

Average target price

62.25 USD

Spread / Average Target

+137.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Q32 BIO INC.	+139.58%	313M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs